Post Profile

PharmaMar completes the patient recruitment for the Phase 3 pivotal study with PM1183

(Pharmamar) PharmaMar announces today that the patient recruitment for the randomized and pivotal Phase III 'CORAIL' study with lurbinectedin (PM1183), for the treatment of platinum-resistant ovarian cancer, has been successfully completed.
read more


Related Posts

NovaRx Initiates Pivotal Phase III Clinical Trial In Lung Cancer Patients

Health : Medical News Today

NovaRx Corporation announced that the company initiated its pivotal Phase III clinical trial of Lucanix(R) (belagenpumatucel-L) in the treatment of advanced non-small cell lung cancer (NSCLC). The first patient enrolled in the study...

PharmaMar announces positive results from its Phase 2 study with PM1183 in BRCA 1/2 MBC

Health : EurekAlert: Health

(Pharmamar) The data was presented at an oral session at the European Society of Medical Oncology.The study meets its primary objective obtaining an overall response rate (ORR) in 41 percent of the patients. In the BRCA 2 subgroup, ...

PharmaMar shows new clinical data on Yondelis® and lurbinectedin at ESMO 2016

Academics / Chemistry : EurekAlert: Chemistry

(Pharmamar) During this congress, PharmaMar will inform in an oral session the results of its Phase II clinical trial with lurbinectedin in patients with BRCA 1/2 metastatic breast cancer.A prospective randomized phase III comparing...

Phase 3 trial with PM1183 in OC continues on the basis of positive recommendation by IDMC

Academics / General Science : Science Codex

PharmaMar (MSE:PHM) announced today that the Independent Data Monitoring Committee (IDMC) has notified the Company of its recommendation that the Phase III (CORAIL) trial currently under way with PM1183 in platinum-resistant ovarian...

PharmaMar Announces The Initiation Of Phase I Clinical Trials With PM1183, A New Antitumor Compound

Health : Medical News Today

PharmaMar SA (Grupo Zeltia, ZEL.MC) announces the initiation of Phase I clinical trials with PM1183, a new antitumor compound developed by PharmaMar's internal research program. The first patient enrolled in the trial has already st...


Copyright © 2016 Regator, LLC